vaginitis, and breastatrophy. Although formal diagnosis and treatment of eating disorders in adolescents are complex and outside the scope of practice for most general obstetrician–gynecologists, it is important that health care providers be comfortable with recognizing and screening at-risk patients. Recognizing risk factors for eating disorders can help to identify patients who should be further with gynecologic concerns or symptoms, including irregular menses, amenorrhea, pelvic pain, atrophic vaginitis, and breastatrophy. * Although formal diagnosis and treatment of eating disorders in adolescents are complex and outside the scope of practice for most general obstetrician–gynecologists, it is important that health care providers be comfortable with recognizing and screening at-risk patients
previously showed interactive effects of time and genotypes of circadian genes on late toxicity after breast radiotherapy and aimed to validate those results in a multi-centre cohort. Clinical and genotype data from 1690 REQUITE breast cancer patients were used with erythema (acute; n=340) and breastatrophy (two years post-radiotherapy; n=514) as primary endpoints. Local datetimes per fraction were (breastatrophy), predictors included BMI, radiation dose, surgery type, treatment time and SNPs in CLOCK (OR 0.62 (95%CI 0.4-0.9); P < 0.01), PER3 (OR 0.65 (95%CI 0.44-0.97); P < 0.04) and RASD1 (OR 0.56 (95%CI 0.35-0.89); P < 0.02). There was a statistically significant interaction between time and genotypes of circadian rhythm genes (CLOCK OR 1.13 (95%CI 1.03-1.23), P < 0.01; PER3 OR 1.1 (95%CI 1.01
irregular menses, amenorrhea, pelvic pain, atrophic vaginitis, and breastatrophy. Although formal diagnosis and treatment of eating disorders in adolescents are complex and outside the scope of practice for most general obstetrician-gynecologists, it is important that health care providers be comfortable with recognizing and screening at-risk patients. Recognizing risk factors for eating disorders can
, including irregular menses, amenorrhea, pelvic pain, atrophic vaginitis, and breastatrophy. Although formal diagnosis and treatment of eating disorders in adolescents are complex and outside the scope of practice for most general obstetrician-gynecologists, it is important that health care providers be comfortable with recognizing and screening at-risk patients. Recognizing risk factors for eating
and examined between March and September 2014. Patients in whom progressive disease had developed or who had undergone further breast surgery were excluded. Local toxicity (fibrosis, telangiectasia, and breastatrophy or retraction) was scored blindly to the treatment received. A logistic regression was run to investigate the effect of treatment sequence after correction for several patient-, treatment interval [CI], 1.34-12.2; P=.013) and the SOMA (Subjective, Objective, Management and Analytic) scale (OR, 3.75; 95% CI, 1.19-11.79; P=.018), as well as grade 2 or 3 breastatrophy or retraction (OR, 3.87; 95% CI, 1.42-10.56; P=.008). No effect on telangiectasia was detected. At long-term follow-up, concomitant chemoradiation therapy has a detrimental effect on both fibrosis and retraction
include cessation of menses, breastatrophy, clitoral enlargement, and voice deepening. Both transsexual females and males experience changes in body fat redistribution, muscle mass, and hair growth. Desired effects from CSHT can take between 3 and 5 years; however, effects that occur during puberty, such as voice deepening and skeletal structure changes, cannot be reversed with CSHT. Decreased sexual
anemia. Pubic and axillary hair growth is usually normal unless a concomitant ACTH deficiency exists.Premenopausal women present with altered menstrual function, ranging from regular anovulatory periods to amenorrhea, as well as hot flashes, decreased libido, breastatrophy, vaginal dryness, and dyspareunia. Postmenopausal women usually present with headache or visual abnormalities due to other
below inframammary fold and no lower pole tissue below nipple; "Snoopy nose" appearance * * Pseudoptosis - Inferior pole ptosis with nipple at or above inframammary fold; usually observed in postpartum breastatrophy Previous Next: IndicationsIn most instances, breast mastopexy has no true medical indications and is performed primarily for aesthetic reasons. The main exception
anemia. Pubic and axillary hair growth is usually normal unless a concomitant ACTH deficiency exists.Premenopausal women present with altered menstrual function, ranging from regular anovulatory periods to amenorrhea, as well as hot flashes, decreased libido, breastatrophy, vaginal dryness, and dyspareunia. Postmenopausal women usually present with headache or visual abnormalities due to other
capacity, and increased cholesterol * * Infants - Hypoglycemia * * Children - Decreased height and growth rate Gonadotrophin deficiency * * Men - Diminished libido and impotence; testes shrink in size, but spermatogenesis generally preserved * * Women - Diminished libido and dyspareunia; breastatrophy in chronic deficiency * * Children - Delayed or frank absence
to the mechanisms and complications that accompany cocaine, alcohol, or opioid abuse.Abuse of AASs has also increased in female athletes of all levels. Additional concerns specific to female abusers include growth of facial hair, male-pattern baldness or regression of frontal hairline, breastatrophy, coarsening of the skin, alteration of the menstrual cycle or amenorrhea, enlargement of the clitoris
anemia. Pubic and axillary hair growth is usually normal unless a concomitant ACTH deficiency exists.Premenopausal women present with altered menstrual function, ranging from regular anovulatory periods to amenorrhea, as well as hot flashes, decreased libido, breastatrophy, vaginal dryness, and dyspareunia. Postmenopausal women usually present with headache or visual abnormalities due to other
to vasoconstriction and increased platelet aggregation. These medications may reduce blood loss by 20-50%. NSAIDs are most effective if used with the onset of menses or just prior to its onset and continued throughout its duration.Danazol creates a hypoestrogenic and hyperandrogenic environment, which induces endometrial atrophy resulting in reduced menstrual loss. Side effects include musculoskeletal pain, breastatrophy, hirsutism, weight gain, oily skin, and acne. Because of the significant androgenic side effects, this drug is usually reserved as a second-line treatment for short-term use prior to surgery.Gonadotropin-releasing hormone agonists may be helpful for short-term use in inducing amenorrhea and allowing women to rebuild their red blood cell mass. They produce a profound hypoestrogenic state similar
to the mechanisms and complications that accompany cocaine, alcohol, or opioid abuse.Abuse of AASs has also increased in female athletes of all levels. Additional concerns specific to female abusers include growth of facial hair, male-pattern baldness or regression of frontal hairline, breastatrophy, coarsening of the skin, alteration of the menstrual cycle or amenorrhea, enlargement of the clitoris
anemia. Pubic and axillary hair growth is usually normal unless a concomitant ACTH deficiency exists.Premenopausal women present with altered menstrual function, ranging from regular anovulatory periods to amenorrhea, as well as hot flashes, decreased libido, breastatrophy, vaginal dryness, and dyspareunia. Postmenopausal women usually present with headache or visual abnormalities due to other
include musculoskeletal pain, breastatrophy, hirsutism, weight gain, oily skin, and acne. Because of the significant androgenic side effects, this drug is usually reserved as a second-line treatment for short-term use prior to surgery.Gonadotropin-releasing hormone agonists may be helpful for short-term use in inducing amenorrhea and allowing women to rebuild their red blood cell mass. They produce
to the mechanisms and complications that accompany cocaine, alcohol, or opioid abuse.Abuse of AASs has also increased in female athletes of all levels. Additional concerns specific to female abusers include growth of facial hair, male-pattern baldness or regression of frontal hairline, breastatrophy, coarsening of the skin, alteration of the menstrual cycle or amenorrhea, enlargement of the clitoris